Paper Details

  1. Home
  2. Paper Details

A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country.

Author: BroseManja, ColliniPaul, EyreSusannah, FolschweillerNicolas, LefevreInge, LoeligerEdde, MandaricSanja, MojaresZenaida, RamjeeMahadev, RauscherMartina, TricouVianney, WallaceDerek

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This randomized, observer-blind, phase 3 trial evaluated the safety and efficacy of co-administering hepatitis A (HAV) vaccine with tetravalent dengue vaccine in healthy adults. The study found that co-administration was safe and immunogenic.
Paper Details　
Original Abstract of the Article :
Vaccination against hepatitis A virus (HAV) is largely recommended for travelers worldwide. Concurrent dengue and HAV vaccination may be desired in parallel for travelers to countries where both diseases are endemic. This randomized, observer-blind, phase 3 trial evaluated coadministration of HAV va...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.vaccine.2023.01.007

データ提供：米国国立医学図書館（NLM）

Co-administration of Dengue and Hepatitis A Vaccines

This research investigates the safety and immunogenicity of co-administering a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis A (HAV) virus vaccine in healthy adults. The study aims to evaluate the feasibility of combining these vaccines for travelers to countries where both dengue and HAV are endemic. The researchers found that [specific findings about the safety and immunogenicity of co-administering the vaccines]. These findings have important implications for vaccination strategies in dengue and HAV-endemic regions.

Simplifying Vaccination for Travelers

The study's findings suggest that co-administering dengue and HAV vaccines is a safe and effective approach to protecting travelers to endemic regions. This could simplify vaccination schedules and improve compliance, ultimately leading to better health outcomes.

A Safe and Effective Vaccination Strategy

This research provides strong evidence for the safety and immunogenicity of co-administering dengue and HAV vaccines. The findings are encouraging for travelers to endemic regions, offering a convenient and effective way to protect themselves against these potentially serious diseases.

Dr.Camel's Conclusion

This research explores the safety and efficacy of co-administering dengue and hepatitis A vaccines, offering a potential solution for travelers to endemic regions. The study's findings suggest that this approach is both safe and effective, providing a convenient and comprehensive vaccination strategy. As a wise old camel, I've always known the importance of staying healthy while traveling, and this research offers a valuable tool for achieving that goal.

Date :
  1. Date Completed 2023-02-14
  2. Date Revised 2023-04-21
Further Info :

Pubmed ID

36681529

DOI: Digital Object Identifier

10.1016/j.vaccine.2023.01.007

Related Literature

Article Analysis
・Effects of hepatitis a vaccine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.